GenFleet Therapeutics announced China’s National Medical Products Administration, or NMPA, has approved the clinical trial application for GFH375 in an open-label, multi-center phase I/II study targeting advanced solid tumor patients with KRAS G12D mutation. GenFleet entered into a discovery and development collaboration with Verastem Oncology in 2023 to advance three oncology programs. The first program selected is GFH375, “which represents a significant milestone as the GenFleet’s first product to achieve overseas out-licensing at preclinical stage and the IND approval in China, underscoring the company’s expertise in the development of RAS-targeted therapies,” the company stated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VSTM:
- Verastem price target lowered to $20 from $34 at Alliance Global Partners
- Verastem price target lowered to $16 from $32 at RBC Capital
- Verastem sinks after 27% response rate in ovarian cancer study
- Verastem initiates rolling submission of avutometinib NDA
- Verastem to present initial interim safety and efficacy results at ASCO